Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.
Mary HwangSarah MedleyFaisal ShakeelBrett VanderwerffMatthew ZawistowskiKelley M KidwellDaniel Louis HertzPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
The finding that patients who carry ALDH1A1 rs8187996 may have a lower risk of cyclophosphamide toxicity than wild-type patients contradicts a prior finding for this variant and should be viewed with skepticism. We found weak evidence that any of these candidate pharmacogenetic predictors of cyclophosphamide toxicity may be useful to personalize cyclophosphamide dosing to optimize therapeutic outcomes in patients with cancer.